SuperGen Inc. (SUPG) MP-470 Demonstrates Clinical Benefit in Lung Cancer Patients
Tweet Send to a Friend
SuperGen Inc., (NASDAQ: SUPG) announced that Phase Ib data for MP-470, its multi-targeted, tyrosine kinase inhibitor and RAD51 suppressor, demonstrated ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
